Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Exercise suppresses tumor growth independent of high fat food intake and associated immune dysfunction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Initial evidence of abnormal brain plasticity in anorexia nervosa: an ultra-high field study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Knockdown of the long noncoding RNA PURPL induces apoptosis and sensitizes liver cancer cells to doxorubicin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Rapid syndromic PCR testing in patients with respiratory tract infections reduces time to results and improves microbial yield

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Exploration of the induced cytokine responses in European Lyme neuroborreliosis: A longitudinal cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic loci

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. High mortality among patients with severe COVID-19 and Do Not Intubate orders

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Passive immunotherapy with convalescent plasma may be the only available agent during the early phases of a pandemic. Here, we report safety and efficacy of high-titer convalescent plasma for COVID-19 pneumonia. Double-blinded randomized multicenter placebo-controlled trial of adult patients hospitalized with COVID-19 pneumonia. The intervention was COVID-19 convalescent plasma and placebo was saline allocated 2:1. The primary outcome was clinical status 14 days after the intervention evaluated on a clinical ordinal scale. The trial was registered at ClinicalTrials.Gov, NCT04345289, 14/04/2020. The CCAP-2 trial was terminated prematurely due to futility. Of 147 patients randomized, we included 144 patients in the modified intention-to-treat population. The ordinal clinical status 14 days post-intervention was comparable between treatment groups (odds ratio (OR) 1.41, 95% confidence interval (CI) 0.72-2.09). Results were consistent when evaluating clinical progression on an individual level 14 days after intervention (OR 1.09; 95% CI 0.46-1.73). No significant differences in length of hospital stay, admission to ICU, frequency of severe adverse events or all-cause mortality during follow-up were found between the intervention and the placebo group. Infusion of convalescent plasma did not influence clinical progression, survival or length of hospitalization in patients with COVID-19 pneumonia.

OriginalsprogEngelsk
Artikelnummer16385
TidsskriftScientific Reports
Vol/bind12
Udgave nummer1
ISSN2045-2322
DOI
StatusUdgivet - 30 sep. 2022

Bibliografisk note

© 2022. The Author(s).

ID: 84750066